Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations

Inclusion Criteria:

• Histological, cytological, or molecular confirmation of recurrent GBM or otherglioma, circumscribed astrocytic glioma, or glioneuronalor neuronal tumors that hasrecurred.

• Radiographically measurable disease.

. -Karnofsky performance status ≥ 60.

• Life expectancy ≥ 12 weeks.

• Documentation of an actionable FGFR1-3 gene mutation or fusion/rearrangement fromtissue : FGFR1-3 fusions or other rearrangements (FGFR1-3 in-frame fusions, anyFGFR2 rearrangement, or FGFR1/3 rearrangement with known partner) or a definedFGFR1-3 activating mutation or in-frame deletion. Only participants with FGFRfusions or rearrangements with an intact kinase domain are eligible.

• MRI-documented objective progression after prior therapy and must have no therapyavailable that is likely to provide clinical benefit.

• Most recent archival tumor specimen must be a tumor block or a minimum of 15unstained slides from biopsy or resection of primary tumor or metastasis.

• Willingness to avoid pregnancy or fathering children.

Exclusion Criteria:

• Prior receipt of an FGFR inhibitor.

• Receipt of anticancer medications or investigational drugs for any indication orreason within 28 days before first dose of study drug.

• Participants may have had treatment for an unlimited number of prior relapses butmust not have had prior bevacizumab or other VEGF/VEGFR inhibitors (exception: priorbevacizumab is allowed if it was administered for the treatment of radiationnecrosis rather than progressive tumor and was stopped at least 12 weeks prior toMRI showing tumor progression).

• Concurrent anticancer therapy

• Candidate for potentially curative surgery.

• Dexamethasone (or equivalent) > 4 mg daily at the time of study registration

• Current evidence of clinically significant corneal or retinal disorder as confirmedby ophthalmologic examination.

• Diffuse leptomeningeal disease.

• Radiation therapy administered within 12 weeks before enrollment/first dose of studydrug.

• Known additional malignancy that is progressing or requires active systemictreatment.